A Relative Bioavailability Study of Bupropion XL 150 mg Tablets Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

July 31, 2004

Study Completion Date

July 31, 2004

Conditions

Healthy

Interventions

DRUG

Abrika Bupropion 150 mg XL Tablet, single dose

A: Experimental Subjects received Abrika formulated products under fasting conditions

DRUG

Wellbutrin XL® 150 mg Tablet, single dose

B: Active comparator Subjects received GlaxoSmithKline formulated products under fasting conditions

Trial Locations (1)

SFBC Ft. Myers, Inc., Fort Myers